title: Evolution of hepatosplenic plasmacytoma in a patient with multiple myeloma receiving chemotherapy.
authors.forename: Pankaj
authors.initials: P
authors.lastname: Malhotra
authors.forename: Pradeep
authors.initials: P
authors.lastname: Bhat
authors.forename: Sushil
authors.initials: S
authors.lastname: Mahi
authors.forename: Sandeep
authors.initials: S
authors.lastname: Chauhan
authors.forename: Arvind
authors.initials: A
authors.lastname: Rajwanshi
authors.forename: Subhash
authors.initials: S
authors.lastname: Varma
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy*; D010954:Plasmacytoma / Q000139:chemically induced* / Q000000981:diagnostic imaging; D011239:Prednisolone / Q000008:administration & dosage; D013160:Splenic Neoplasms / Q000139:chemically induced* / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed
chemical_list: D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D011239:Prednisolone; D008558:Melphalan